How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →
API Evangelist API Evangelist
Discovery
Learnings
Guidance
Toolbox
Alignment
API Evangelist LLC

Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing

calendar_today November 13, 2026 person Vandana Singh domain benzinga

Zai Lab Limited (NASDAQ:ZLAB) reported preliminary results from the first-in-human portion of its global Phase 1/1b clinical trial evaluating ZL-1503, an investigational bispecific antibody for moderate-to-severe atopic dermatitis. Strong Biomarker Inhibition And Extended Half-Life Data from 48 healthy volunteers showed that ZL-1503 rapidly and sustainably blocked the IL-13 pathway. A single dose of 200 mg or higher inhibited phosphorylated STAT6, a key atopic dermatitis signaling biomarker, by at least 90% through Week 12.

open_in_new Read original post